噬菌体展示禽流感病毒抗原变异性基因片段文库的构建

构建T7噬菌体展示禽流感病毒抗原变异性基因片段文库. 首先， 从Gene Bank中查找筛选禽流感病毒抗原变异性基因, 将其截短、 修饰、 简并后得到禽流感病毒抗原变异性基因微阵列. 其次， 将合成的禽流感病毒抗原变异性基因片段文库扩增、 酶切, 链接到双酶切后的T7噬菌体载体基因上, 构成重组噬菌体DNA. 最后， 重组噬菌体DNA经体外包装和扩增, 得到T7噬菌体展示文库, 并进行T7噬菌体展示文库滴度、 重组率和免疫活性测定. 实验结果表明, 从Gene Bank中查找、 筛选、 剪切和修饰共获得96 258条序列构建T7噬菌体展示文库, 原始文库滴度为3.6×107个菌落/mL, 重组率大于90%. 用禽流感病毒H5N1抗体进行捕获, 经聚合酶链式反应(PCR)鉴定, 得到理想目的条带, 证明噬菌体表面展示蛋白具有抗原活性, 可用于禽流感病毒感染患者的快速检测及抗原表位筛选.     

Win32侵染式病毒的宿主入口技术

分析了Win32病毒编制中宿主入口技术的原理并给出了实现这种技术的流程,并基于此原理,初步提出了利用加壳和校检码检测来对抗宿主入口技术的设想.     

感染病毒机器的控制和处理方法探析

由于病毒给网络的正常运行带来很大的危害,中毒机器应该及时处理.在主要利用域名系统和防火墙的功能的基础上,研究和设计出一种引导用户自己解决病毒问题的思路和方法,一定程度上减轻了网管人员的工作量,从而更加有效地管理校园网.     

计算机免受病毒侵扰防范技术

计算机病毒严重干扰了计算机的工作,已引起社会各界与用户的普遍关注.本文依据计算机病毒的有关知识,结合工作实践,就如何预防和消除病毒,谈一点看法.     

Biological role of major transplantation antigens in T cell self-recognition

Summary The proposal is made, illustrated and supported by experimental evidence that T cell-mediated immunopathology triggered initially by low- or non-cytopathic infectious agents may cause diseases, susceptibility to which is linked to the major histocompatibility gene complex.This summary is an updated version of the paper given on the occasion of the Paul Ehrlich Prize ceremonies in 1983; it was also presented at the meeting New Trends in Allergy II in München 1985, and is reproduced here with the permission of Springer Verlag, Heidelberg.     

保证计算机资源安全的一种新方法

通过对计算机硬盘刊物控制的方法来避免计算机病毒地系统的侵在,以达到保证计算机资源安全的目的。     

免疫鸡群新城疫病毒检测和分离的研究

以ＳＰＦ鸡抗新城疫病毒（ＮＤＶ）ＩｇＧ为包被抗体（５μｇ／ｍＬ）,兔抗ＮＤＶＶｅｒｏ细胞培养纯化毒ＩｇＧ为第二抗体（１∶２００～６００）,酶标记羊抗兔ＩｇＧ（１∶５０００）为指示抗体建立间接夹心ＥＬＩＳＡ,检测实验免疫鸡、攻毒鸡及现地免疫鸡口腔或泄殖腔外分泌物。结果表明：新城疫无毒力Ｖ４疫苗免疫后２ｄ,口腔内病毒抗原随机检出率为４／１０,第１０天为１０／１０;泄殖腔为０～１／１０,并持续１８ｄ以上。滴鼻攻毒后１ｄ,口腔和泄殖腔内病毒抗原检出率分别是８／１０和６／１０;第１３天,泄殖腔内病毒抗原检出阴性。ＮＤＶ灭活疫苗免疫６０ｄ后攻毒,第２天有７／２０口腔和８／２０泄殖腔检出阳性,并一直到攻毒后第１４天。非免疫对照鸡攻毒后第３天直到死亡时,口腔和泄殖腔均可检出病毒抗原。对各地临床上无任何症状的ＮＤＶ免疫鸡群检测发现,泄殖腔ＮＤＶ抗原阳性率０％～９．３％,分离到８株ＮＤＶ流行毒株,生物学试验证实这些毒株的毒力属中等毒力偏强或强毒。     

Research advances in gene therapy for Parkinson's disease

During the long period of time when people have been seeking for an effective therapeutic method for PD, the gene therapy has shown greater and greater advantages over other methods. It can be performed mainly in two ways: ex vivo and in vivo. With the former, TH gene as well as some neurotrophic factor genes (such as GDNF, BNDF genes) can be invited to some cell lines or primary cells thus forming engineered cells and then implanting them into brain. While with the latter, viral vectors including HSV-1, Ad, AAV that can be utilized to construct recombinant viruses, or non-virus vectors can be used to delived DNA into brain directly. The present review summarizes the recent research advances in the gene therapy for PD, and it is reasonable for us to predict a notable progress in prevention and treatment for PD in the next decade.